Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 5天前
Hutchison China MediTech Limited (HCM) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. Hutchison China MediTech Limited (NASDAQ: HCM)Q2 2020 Earnings CallJul 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Mr.
Motley Fool · 07/31 03:01
Hutchison China MediTech reports 1H results
Hutchison China MediTech (NASDAQ:HCM): 1H GAAP EPADS of -$0.36. Revenue of $106.77M (+4.5% Y/Y) Press Release
seekingalpha · 07/30 16:13
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in MET3 Exon 14 skipping mutati
Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.